Benitec Corp (BNTC) - Business Payback Period

Corporate emblem and logo of Benitec Corp (BNTC)

Exclusive FDA rights and robust patent protection create significant barriers to entry for new players in the niche. Benitec Biopharma Inc. (BNTC) leverages its innovative ddRNAi platform to develop one-time treatments for severe hereditary pathologies. However, a lack of profitability and dependence on capital render its financial position unstable. The market capitalization trend is fixed at -7.00, illustrating the current stage of clinical trials.

BNTC: Benitec P/E Multiple 07/04/2022 - 11/13/2026

Analytical breakdowns for Benitec (BNTC)

- current price and projected stock value:
Share Price benitec.com|BNTC - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Benitec Biopharma Inc.|BNTC - Real Price to Acquire Entire Company
- book capitalization data:
Book Price of a Share Benitec Biopharma|BNTC - Book Capitalization|Market-to-Book Ratio benitec.com|BNTC - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Benitec Biopharma Inc.|BNTC - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Benitec Corp|BNTC - Company Aggregate Debts|Debt to Book Capitalization Ratio Benitec Biopharma Inc.|BNTC - Company Long-Term Debts|Short-Term Debt Volume Benitec Biopharma|Immediate Liquidity benitec.com
- earnings and valuation multiples information:
BNTC - Company Net Income|Forward Earnings Benitec Biopharma Inc.|BNTC - P/E Multiple|Future Price to Earnings Multiple Benitec Biopharma Inc|BNTC - PEG Multiple|EV/EBITDA Multiple Benitec Biopharma Inc.|BNTC - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Benitec Biopharma|BNTC - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months benitec.com|BNTC - Earnings growth in current year|Earnings growth forecast for next year Benitec Biopharma Inc.
Summary company analysis:benitec.com
Signature product of Benitec Corp

Benitec Biopharma Inc. (BNTC) focuses on developing innovative ddRNAi drugs for the therapy of rare genetic pathologies. Analyzing the Benitec Biopharma Inc. (BNTC) P/E chart, an investor sees the ratio of current market capitalization to net earnings per share. This multiple determines the cost of each dollar of earnings, allowing for an assessment of whether the asset is overvalued or undervalued. For a biopharmaceutical startup, such a metric serves as an indicator of market expectations regarding the future success of clinical trials.

Key competitors

Price to Earnings Multiple TEM (Tempus AI Inc)|P/E Multiple QGEN|Business Payback Period Ionis Pharmaceuticals, Inc.|Repligen Corp. - Price to Earnings Ratio|Market Price to Net Income Ratio RNA (Avidity Corp)|CRISPR Therapeutics AG - P/E Multiple|Market Cap to Earnings genedx.com|RARE: P/E Multiple|Price to Earnings Ratio Beam Therapeutics Inc|Price to Earnings Ratio SRPT|TWST: Company Value to Net Income|P/E Multiple TXG|Price to Earnings Ratio NTLA (intelliatx.com)|P/E Multiple STOK (Stoke Therapeutics, Inc.)|Business Payback Period BioLife Solutions Inc (BLFS)|WVE - Price to Earnings Ratio|Market Cap to Earnings Maze Therapeutics Corp|Sionna Therapeutics Inc (SION) - Price to Earnings Ratio|Market Cap to Net Income PRME (primemedicine.com)|TSHA (Taysha Gene Therapies, Inc.) - P/E Multiple|QURE: Company Value to Net Income|P/E Multiple MGTX|P/E Multiple REGENXBIO Corp (RGNX)|Price to Earnings Ratio Solid Biosciences Inc. SLDB|Company Value to Net Income OCGN|PACB - Price to Earnings Ratio|Design Therapeutics Inc (DSGN) - Price to Earnings Ratio|RCKT: P/E Multiple|4D Molecular Corp (FDMT) - P/E Multiple|Price to Earnings Ratio LXEO|KRRO: Company Value to Net Income|P/E Multiple EDIT|Business Payback Period Silence Therapeutics PLC|Price to Earnings Ratio ProQR Therapeutics PRQR|CDXS: Price to Earnings Multiple|Sangamo Therapeutics - P/E Multiple|Nautilus Biotechnology (NAUT) - Price to Earnings Ratio|MGX (Metagenomi) - Price to Earnings Ratio|DTIL - Business Payback Period|GBIO (Generation Bio Co) - P/E Multiple|Price to Earnings Ratio BOLD|Price to Earnings Ratio Exicure, Inc. (XCUR)|imunon.com - Price to Earnings Multiple|Phio Pharmaceuticals Corp. - Price to Earnings Ratio|Market Price to Net Income Ratio MBIO (Mustang Bio Inc)|TransCode - P/E Multiple|Bionano Genomics, Inc. (BNGO) - Price to Earnings Ratio|APDN: P/E Multiple|Price to Earnings Multiple BLUE|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd|Price to Earnings Multiple OMGA (Omega Therapeutics Inc)|P/E Multiple OMIC|P/E Multiple Regulus (RGLS)|P/E Multiple SYRS (Syros Pharmaceuticals)|telesisbio.com - Price to Earnings Ratio|TRACON Pharmaceuticals, Inc. - P/E Multiple|Market Cap to Earnings Unity Biotechnology Inc.